The visceral adiposity index, lipid accumulation product, and plasma atherogenic index are associated with subclinical atherosclerosis in patients with newly diagnosed acromegaly

Results: The PAI, VAI, LAP, and CIMT values were significantly higher in patients with acromegaly compared with the control subjects (p < 0.004, p < 0.027, p

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Background /aim: Acromegaly is a rare chronic endocrine disorder, the active form of which is associated with an increased risk of cardiovascular and metabolic disease.

📊

Key Findings & Data:Materials and methods: The study included 45 patients newly diagnosed with acromegaly and 45 age–sex matched healthy control subjects.

💡

Conclusion & Impact:Results: The PAI, VAI, LAP, and CIMT values were significantly higher in patients with acromegaly compared with the control subjects (p < 0.004, p < 0.027, p

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Background /aim: Acromegaly is a rare chronic endocrine disorder, the active form of which is associated with an increased risk of cardiovascular and metabolic disease. Therefore, early diagnosis and treatment of cardiovascular diseases in acromegaly patients are important in terms of morbidity and mortality. The aim of this study was to determine whether the visceral adiposity index (VAI), lipid accumulation product (LAP), and plasma atherogenic index (PAI) are early cardiovascular risk markers in patients with active acromegaly. Materials and methods: The study included 45 patients newly diagnosed with acromegaly and 45 age–sex matched healthy control subjects. The VAI, LAP, and PAI values were calculated, and carotid artery intima media thickness (CIMT) was measured in both the patients and control groups. Results: The PAI, VAI, LAP, and CIMT values were significantly higher in patients with acromegaly compared with the control subjects (p < 0.004, p < 0.027, p

🔖

Cite This Article

ÖZBEK, M., ÇAKAL, E., ÇALAPKULU, M., BOSTAN, H., ÜNSAL, İ. Ö., HEPŞEN, S., SENCAR, M. E. (2022). The visceral adiposity index, lipid accumulation product, and plasma atherogenic index are associated with subclinical atherosclerosis in patients with newly diagnosed acromegaly. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 5, 2600–2606. https://ajindex.com/articles/609534

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

Gadelha MR, Kasuki L, Lim DST, Fleseriu M. Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update. Endocrine Reviews 2019; 40(1): 268-332. doi: 10.1210/er.2018-00115 2. Melmed S. Acromegaly pathogenesis and treatment. Journal of Clinical Investigation 2009; 119(11): 3189-3202. doi: 10.1172/ JCI39375 3. Moller N, Jorgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocrine Reviews 2009; 30(2): 152-177. doi: 10.1210/er.2008-0027 4. Frara S, Maffezzoni F, Mazziotti G, Giustina A. Current and Emerging Aspects of Diabetes Mellitus in Acromegaly.Trends in Endocrinology & Metabolism 2016; 27(7): 470-483. doi: 10.1016/j.tem.2016.04.014 5. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management. Endocrine Reviews 2004; 25(1): 102–152. doi: 10.1210/er.2002-0022 6. Dogansen SC, Yalin GY, Tanrikulu S, Yarman S. Impact of glucose metabolism disorders on IGF-1 levels in patients with acromegaly. Hormone Metabolism Research 2018; 50: 408- 413. doi: 10.1055/a-0594-2404 7. Mercado M,Ramírez-Rentería C. Metabolic complications of acromegaly. Frontiers Hormone Research 2018; 49: 20-28. doi: 10.1159/000486001 8. Amato MC, Giordano C, Galia M, Criscimanna A, Vitabile S et al.Visceral Adiposity Index: a reliable indicator of visceral fat function associated with cardiometabolic risk. Diabetes Care 2010; 33(4): 920-922. doi: 10.2337/dc09-1825 9. A. Ciresi, M. C. Amato, G. Pizzolanti, C. Giordano Galluzzo. Visceral Adiposity Index Is Associated with Insulin Sensitivity and Adipocytokine Levels in Newly Diagnosed Acromegalic Patients. Journal of Clinical Endocrinology and Metabolism 2012; 97(8): 2907–2915. doi: 10.1210/jc.2012-1518 10. A. Ciresi, M. C. Amato, R. Pivonello, E. Nazzari, L. F. Grasso et al. The Metabolic Profile in Active Acromegaly is GenderSpecific. Journal of Clinical Endocrinology and Metabolism 2013; 98(1): E51-E59. doi: 10.1210/jc.2012-2896 11. Kahn HS. The “lipid accumulation product” performs better than the body mass index for recognizing cardiovascular risk: a population-based comparison. BMC Cardiovascular Disorders 2005; 8(5): 26 doi: 10.1186/1471-2261-5-26 12. Vieira JN, Braz MAD, Gomes FO, Silva PRD, Santos OTM et al. Cardiovascular risk assessment using the lipid accumulation product index among primary healthcare users: a crosssectional study. Sao Paulo Medical Journal 2019; 137(2): 126- 13